<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689010</url>
  </required_header>
  <id_info>
    <org_study_id>AZAF-1703</org_study_id>
    <nct_id>NCT03689010</nct_id>
  </id_info>
  <brief_title>To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Taro Product to RLD, and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of the efficacy of the test and reference products over that
      of the placebo control in the treatment of moderate facial rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group study, comparing
      test and reference products and both active treatments to a placebo control in the treatment
      of Moderate Facial Rosacea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">August 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1116</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Azelaic acid foam 15%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finacea® (azelaic acid) Foam, 15%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelaic acid foam 15%</intervention_name>
    <description>Azelaic acid foam 15%</description>
    <arm_group_label>Azelaic acid foam 15%</arm_group_label>
    <other_name>AZAF 1703</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finacea® (Azelaic acid Foam) 15%</intervention_name>
    <description>Azelaic acid foam 15%</description>
    <arm_group_label>Finacea® (azelaic acid) Foam, 15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of the test product</intervention_name>
    <description>Vehicle of the test product</description>
    <arm_group_label>Vehicle of the test product</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥ 18 with a clinical diagnosis of facial
             rosacea.

          -  Subjects must have provided IRB approved written informed consent.

        Exclusion Criteria:

          -  Female Subjects who are pregnant, nursing or planning to become pregnant during study
             participation.

          -  Subjects who have used estrogens or oral contraceptives for less than 3 months prior
             to baseline; use of such therapy must remain constant throughout the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

